|
Real-time Estimate
Cboe BZX
23:29:07 20/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 288.76 USD | +1.84% |
|
-2.09% | +26.43% |
| 11-19 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 11-19 | AbbVie, Disco Pharmaceuticals Enter Solid Tumor Collaboration, Option-to-License Deal | MT |
| Market Cap | 501B 456B 421B 383B 718B 46,410B 754B 5,119B 2,035B 25,349B 1,880B 1,841B 79,556B | P/E 2026 * |
36.1x | P/E 2027 * | 26.6x |
|---|---|---|---|---|---|
| Enterprise Value | 564B 514B 474B 431B 808B 52,265B 850B 5,765B 2,291B 28,547B 2,118B 2,073B 89,592B | EV / Sales 2026 * |
8.33x | EV / Sales 2027 * | 7.5x |
| Free-Float |
95.64% | Yield 2026 * |
2.43% | Yield 2027 * | 2.56% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| ABBV | Delayed | |
| ABBV | Real-time | ||
| 4AB | Real-time | ||
| ABBV * | End-of-day quote | ||
| 4AB | Delayed | ||
| 4AB | Real-time | ||
| Real-time | |||
| ABBV | Delayed | ||
| 0QCV | Delayed | ||
| 1ABBV | End-of-day quote | ||
| 4AB | Delayed | ||
| 4AB | Delayed | ||
| ABBV | Delayed | ||
| ABBV | End-of-day quote | ||
| 0QCV | Real-time | ||
| ABBV | End-of-day quote | ||
| ABBVCL | End-of-day quote |
Last Transcript: AbbVie Inc.
| 1 day | +1.86% | ||
| 1 week | -2.09% | ||
| Current month | -2.04% | ||
| 1 month | -0.07% | ||
| 3 months | +10.33% | ||
| 6 months | +36.07% | ||
| Current year | +26.43% |
| 1 week | 279.88 | 301.2 | |
| 1 month | 278.01 | 302.93 | |
| Current year | 190.75 | 302.93 | |
| 1 year | 190.75 | 302.93 | |
| 3 years | 137.65 | 302.93 | |
| 5 years | 115.01 | 302.93 | |
| 10 years | 58.6 | 302.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 55 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 59 | 23/06/2022 |
Linda Ray
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 65 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 74 | 01/01/2013 |
Ed Rapp
BRD | Director/Board Member | 69 | 01/01/2013 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 30/09/26 | Free | Director | 59 | 0.0000% | ||
| 30/09/26 | Free | Director | 129 | 0.0000% | ||
| 14/08/26 | Exercice | Executive/Senior Manager | 98,130 | 0.0056% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.84% | -2.09% | +25.90% | +108.86% | 501B | ||
| -0.02% | -6.34% | +29.59% | +126.24% | 1,204B | ||
| +1.75% | -4.83% | +33.92% | +81.42% | 643B | ||
| -0.60% | -1.95% | +27.26% | +67.32% | 378B | ||
| +1.28% | -8.76% | +41.96% | +31.30% | 327B | ||
| +0.41% | -4.70% | +27.23% | +51.59% | 285B | ||
| +0.81% | -4.08% | -1.74% | +32.71% | 270B | ||
| +0.17% | -6.04% | +30.19% | +64.89% | 237B | ||
| +0.80% | -0.02% | +34.45% | +121.12% | 207B | ||
| -0.25% | -5.01% | -15.80% | -62.38% | 172B | ||
| Average | +0.61% | -4.35% | +23.30% | +62.31% | 422B | |
| Weighted average by Cap. | +0.64% | -4.67% | +26.82% | +82.34% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 67.79B 61.75B 56.9B 51.75B 97.09B 6,278B 102B 692B 275B 3,429B 254B 249B 10,761B | 74.02B 67.42B 62.12B 56.51B 106B 6,854B 111B 756B 301B 3,744B 278B 272B 11,750B |
| Net income | 14.35B 13.07B 12.04B 10.96B 20.55B 1,329B 21.6B 147B 58.26B 726B 53.84B 52.71B 2,278B | 19.32B 17.59B 16.21B 14.75B 27.67B 1,789B 29.08B 197B 78.43B 977B 72.48B 70.95B 3,066B |
| Net Debt | 63.23B 57.59B 53.06B 48.27B 90.55B 5,855B 95.17B 646B 257B 3,198B 237B 232B 10,036B | 54.29B 49.45B 45.56B 41.44B 77.75B 5,027B 81.71B 555B 220B 2,746B 204B 199B 8,617B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/11/26 | $288.85 | +1.87% | 2,892,019 |
| 19/11/26 | $283.54 | -0.86% | 5,047,453 |
| 18/11/26 | $286.01 | -2.33% | 4,842,258 |
| 17/11/26 | $292.82 | -0.59% | 3,950,014 |
| 16/11/26 | $294.55 | -0.16% | 5,493,798 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
















